In addition, inhibition of this pathway perturbs redox homeostasis by downregulating NADPH production [20]; thus we suggest that inhibition of MACC1-AS1/MACC1 might result in synergetic anti-tumor effects, when combined with the clinical application of HGF/c-MET inhibitors, by targeting metabolic plasticity. The gene discussed is MACC1; the disease is neoplasm.